News

Massachusetts health insurers are effectively telling the drug companies that they may seek a rapidly growing customer base ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...
Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...
U.S. stocks climbed near their all-time high after oil prices eased further on hopes that Israel’s war with Iran will not damage the global flow of crude.
If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates ...
Cigna now offers employers $200 Wegovy, Zepbound copay option The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.
In February, Eli Lilly cut the monthly price for lower-dosage vials of its obesity drug Zepbound by $50 for consumers who pay cash via the drugmaker's LillyDirect website.
However, investors have been concerned that Wegovy has lost its lead in the weight-loss market to Zepbound, an injection manufactured by rival firm Eli Lilly — and Novo Nordisk's share price has ...
Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes a look at how compounding became a multibillion dollar industry.
Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.
Amazon is not planning to list added tariff costs next to product prices on its site — despite speculation spanning from a report that claimed the e-commerce giant would soon show new import ...